Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Inken Terjung"'
Autor:
Heather Scharpenseel, Florian Malchers, Inken Terjung, Axel Hillmer, Sabine Merkelbach-Bruse, Andreas H. Scheel, Janna Siemanowski, Matthias Scheffler, Richard Riedel, Anna Eisert, Sebastian Yves Friedrich Michels, Rieke Nila Fischer, Jan-Philip Weber, Theresa Westphal, Anna Kron, Juliane Sueptitz, Roman K. Thomas, Reinhard Buettner, Juergen Wolf, Lucia Nogova
Publikováno v:
Journal of Clinical Oncology. 40:e21013-e21013
e21013 Background: The fibroblast growth factor receptor (FGFR) 1-4 genes show a heterogenic landscape of alterations in non-small cell lung cancer (NSCLC) whereas only a small amount is yet considered to have oncogenic potential. The frequency of ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d81d1dc9ddc5af139d1e1c755ab87290
https://doi.org/10.1200/jco.2022.40.16_suppl.e21013
https://doi.org/10.1200/jco.2022.40.16_suppl.e21013
Autor:
Moritz Glaser, Cornelia von Levetzow, Sebastian Yves Friedrich Michels, Lucia Nogova, Marianna Katzenmeier, Claudia Wompner, Jaqueline Schmitz, Elisabeth Bitter, Inken Terjung, Elke Passmann, Diana Schaufler, Anna Eisert, Rieke Nila Fischer, Richard Riedel, Jan-Phillip Weber, Sabine Hahne, Sabine Merkelbach-Bruse, Reinhard Büttner, Juergen Wolf, Matthias Scheffler
Publikováno v:
Journal of Clinical Oncology. 40:e21117-e21117
e21117 Background: Fusions in the ROS1 proto-oncogene are among the best treatable genetic aberrations in Non-small cell lung cancer (NSCLC). Besides the occurrence of solvent-front mutations (SFM) in acquired resistance to targeted therapy, little i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b679b1981f30091887866e02df135caa
https://doi.org/10.1200/jco.2022.40.16_suppl.e21117
https://doi.org/10.1200/jco.2022.40.16_suppl.e21117